reports
Medivir AB: 1 director
A director at Medivir AB maiden bought 25,000 shares at 8.114SEK and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...
- MarketLine Department
Achillion Pharmaceuticals, Inc. - Mergers & Acquisitions (M&A), Partne...
Summary Marketline's Achillion Pharmaceuticals, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Achillion Pharmaceuticals, Inc. since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensiv...
A director bought 17,066 shares at 37.941SEK and
A director at Medivir Ab bought 17,066 shares at 37.941SEK and the significance rating of the trade was 66/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...
Ford Equity International Rating and Forecast Report
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...
Medivir: Medivir’s Nucleotide Polymerase Inhibitor for the Treatment...
STOCKHOLM--(BUSINESS WIRE)-- Regulatory News: Medivir AB (Nasdaq Stockholm: MVIR) (STO:MVIRB) today announces that MIV-818 has been selected as a candidate drug (CD) from its nucleotide DNA polymerase inhibitor project for the treatment of hepatocellular carcinoma (HCC), and has now entered non-clinical development. Liver cancers are orphan indications in North American and Western European markets. However they are the second leading cause of cancer-related death worldwide, and one of the fastest growing forms of ...
Medivir Divests Its Pharmaceutical Company BioPhausia (Nordic Brands) ...
STOCKHOLM--(BUSINESS WIRE)-- Regulatory News: Medivir AB (Nasdaq Stockholm: MVIR) today announces that the company has entered into an agreement with Karo Pharma AB regarding the sale of Medivir’s subsidiary BioPhausia AB (Nordic Brands) to Karo Pharma. The purchase price will be SEK 908 million on a cash and debt free basis, including a normalized working capital. The transaction is expected to close by mid-December 2016. Background and rationale As previously communicated through press releases in J...
Medivir Focuses Exclusively on Oncology and Reorganizes to Significant...
STOCKHOLM--(BUSINESS WIRE)-- Regulatory News: Medivir AB (Nasdaq Stockholm: MVIR) today announces a reorganization of the company and a significant cost reduction in both early research and administrative functions. The board has decided that the company onwards will have an exclusive focus on oncology, utilizing both of Medivir´s technology platforms and competences in protease inhibition and nucleotide-/nucleoside science. Partnering discussions for all remaining infectious disease assets in the R&D pipeline will be initiat...
Medivir: Updated Interim Phase IIa Data Demonstrate That the Combinati...
HUDDINGE, Sweden--(BUSINESS WIRE)-- Regulatory News: Medivir AB (STO:MVIRB) today announced that updated interim data from a phase IIa study being conducted by Alios BioPharma Inc., part of the Janssen Pharmaceutical Companies (Janssen), were presented on September 23rd at the European Association for the Study of the Liver (EASL) Special Conference in Paris, France. The updated results, which include expanded safety and efficacy data, were presented in the ePoster entitled "Short duration treatment with AL-33...
Medivir: MIV-711 Osteoarthritis Trial: Recommendation to Go Ahead Base...
STOCKHOLM--(BUSINESS WIRE)-- Regulatory News: Medivir AB (Nasdaq Stockholm: MVIR) today announces new information about its phase IIa program for the treatment of osteoarthritis: · The independent Data Monitoring Committee (DMC) has recommended continuation of the ongoing randomized, double-blind phase IIa study (MIV-711-201) based on a review of unblinded safety data. · The first patient has been enrolled into an open label phase IIa extension study, MIV-711-202. The objective of MIV-711-201...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.